Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431221 | 0.86 | HTT (0.62) | HTTKMT2AKLK7SMN1; SMN2F2RL1 | |
| SCHEMBL924496 | 0.86 | KMT2A (0.63) | HTTKMT2AGLAKLK7MEN1 | |
| SCHEMBL15334365 | 0.85 | GAA (0.52) | HTTKMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL10763604 | 0.84 | F2RL1 (0.73) | KMT2AGLASMN1; SMN2F2RL1LMNA | |
| SCHEMBL12704024 | 0.84 | HTT (0.53) | HTTKMT2AGLAKLK7MEN1 | |
| SCHEMBL4077327 | 0.83 | KMT2A (0.49) | KMT2ASMN1; SMN2LMNAGAA | |
| SCHEMBL699965 | 0.82 | KDM4E (0.50) | KMT2AMEN1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL21572817 | 0.82 | CYP4Z1 (0.46) | KMT2AMEN1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL622329 | 0.82 | MAPT (0.61) | KMT2AMEN1SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14390296 | 0.82 | CYP4Z1 (0.46) | KMT2AMEN1SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109942523-B | Benzofuran and benzofuran coumarin derivatives, and preparation method and application thereof | 华东师范大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-108997242-B | Substituted phenyl pyrazolone derivative, preparation and application | 浙江大学 | 2020-10-20 | — | — | CN | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227930-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBVIE INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES | 2014-10-16 | — | — | US | disclosed |
| US-8846743-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846743-B2 | Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2603481-B1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO KG (DE) | 2014-09-17 | — | — | EP | disclosed |
| US-8637674-B2 | Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2014-01-28 | — | — | US | disclosed |
| EP-2603481-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2013-06-19 | — | — | EP | disclosed |
| US-20120232117-A1 | PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-09-13 | — | — | US | disclosed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020131-A2 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309206-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | HTT 574/4885KMT2A 1304/4885GLA 3169/4885 |
| US-20120040948-A1 | AMINOINDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, BCAT1, GFPT1 | HTT 574/4885KMT2A 1304/4885GLA 3169/4885 |
| US-20120232117-A1 | PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND COMPOSITION FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS CONTAINING SAME | PTH1R, VDR, SOST | HTT 3951/4885KMT2A 3628/4885GLA 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.